SCHEMBL14033971

SCHEMBL14033971

Clc1ccc(C(Cl)c2cccc3cccnc23)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.47
GAA P10253 2/20 0.47
KDR P35968 2/20 0.47
HSP90AA1 P07900 5/20 0.45
P4HB P07237 1/20 0.45
PAX8 Q06710 1/20 0.45
PSMD14 O00487 1/20 0.44
COPS5 Q92905 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
LMNA P02545 2/20 0.44
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
SLC40A1 Q9NP59 1/20 0.43
TP53 P04637 2/20 0.42
MAPT P10636 2/20 0.42
MMP2 P08253 2/20 0.42
TSHR P16473 2/20 0.42
KDM4E B2RXH2 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
GMNN O75496 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14033102 0.83 HSP90AA1 (0.47) L3MBTL1GAAKDRHSP90AA1P4HB
SCHEMBL9876503 0.77 PSMD14 (0.55) L3MBTL1GAAHSP90AA1PSMD14COPS5
SCHEMBL14033666 0.76 PABPC1 (0.48) L3MBTL1SMN1; SMN2LMNAKMT2AMEN1
SCHEMBL28220687 0.74 PSMD14 (0.52) L3MBTL1GAAHSP90AA1PSMD14COPS5
SCHEMBL28037486 0.74 PSMD14 (0.52) L3MBTL1GAAHSP90AA1PSMD14COPS5
SCHEMBL17541536 0.74 PSMD14 (0.52) L3MBTL1GAAHSP90AA1PSMD14COPS5
SCHEMBL14033462 0.73 CYP2C19 (0.47) L3MBTL1LMNAMAPTTSHRKDM4E
SCHEMBL9864313 0.72 PSMD14 (0.42) GAAHSP90AA1PSMD14COPS5SMN1; SMN2
SCHEMBL14034054 0.72 LMNA (0.48) L3MBTL1KDRSMN1; SMN2LMNATP53
SCHEMBL27536022 0.71 PSMD14 (0.48) L3MBTL1GAAHSP90AA1PSMD14COPS5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432268-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2008-10-07 US disclosed
US-7432268-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2008-10-07 US disclosed